AU2017222700B2 - Multi-specific molecules - Google Patents

Multi-specific molecules Download PDF

Info

Publication number
AU2017222700B2
AU2017222700B2 AU2017222700A AU2017222700A AU2017222700B2 AU 2017222700 B2 AU2017222700 B2 AU 2017222700B2 AU 2017222700 A AU2017222700 A AU 2017222700A AU 2017222700 A AU2017222700 A AU 2017222700A AU 2017222700 B2 AU2017222700 B2 AU 2017222700B2
Authority
AU
Australia
Prior art keywords
ser
gly
val
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017222700A
Other languages
English (en)
Other versions
AU2017222700A1 (en
Inventor
Phil Anthony JENNINGS
George Kopsidas
Michael Ross Luke
Anthony Simon ROBERTS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imunexus Therapeutics Ltd
Original Assignee
Imunexus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900708A external-priority patent/AU2016900708A0/en
Application filed by Imunexus Therapeutics Ltd filed Critical Imunexus Therapeutics Ltd
Publication of AU2017222700A1 publication Critical patent/AU2017222700A1/en
Application granted granted Critical
Publication of AU2017222700B2 publication Critical patent/AU2017222700B2/en
Priority to AU2019200005A priority Critical patent/AU2019200005A1/en
Assigned to Imunexus Therapeutics Limited reassignment Imunexus Therapeutics Limited Request for Assignment Assignors: IMUNEXUS PTY LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • C07K14/765Serum albumin, e.g. HSA
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/522CH1 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • C07K2318/20Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/33Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2017222700A 2016-02-26 2017-02-27 Multi-specific molecules Active AU2017222700B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019200005A AU2019200005A1 (en) 2016-02-26 2019-01-02 Multi-specific molecules

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016900708A AU2016900708A0 (en) 2016-02-26 Multi-specific molecules 1
AU2016900709 2016-02-26
AU2016900708 2016-02-26
AU2016900709A AU2016900709A0 (en) 2016-02-26 Multi-specific molecules 2
PCT/AU2017/050168 WO2017143406A1 (en) 2016-02-26 2017-02-27 Multi-specific molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019200005A Division AU2019200005A1 (en) 2016-02-26 2019-01-02 Multi-specific molecules

Publications (2)

Publication Number Publication Date
AU2017222700A1 AU2017222700A1 (en) 2018-03-22
AU2017222700B2 true AU2017222700B2 (en) 2018-09-27

Family

ID=59685848

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017222700A Active AU2017222700B2 (en) 2016-02-26 2017-02-27 Multi-specific molecules
AU2019200005A Abandoned AU2019200005A1 (en) 2016-02-26 2019-01-02 Multi-specific molecules

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019200005A Abandoned AU2019200005A1 (en) 2016-02-26 2019-01-02 Multi-specific molecules

Country Status (7)

Country Link
US (4) US20190338013A1 (enExample)
EP (1) EP3419667A4 (enExample)
JP (3) JP7536424B2 (enExample)
CN (1) CN109310766A (enExample)
AU (2) AU2017222700B2 (enExample)
TW (1) TW201734037A (enExample)
WO (1) WO2017143406A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017143406A1 (en) * 2016-02-26 2017-08-31 Imunexus Pty Ltd Multi-specific molecules
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
MX2019013648A (es) 2017-05-19 2021-01-08 Wuxi Biologics Shanghai Co Ltd Anticuerpos monoclonales novedosos para proteina 4 asociada con el linfocito t citotoxico (ctla-4).
EP3668893A4 (en) * 2017-08-16 2021-08-04 Dragonfly Therapeutics, Inc. PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
TW201930349A (zh) * 2018-01-08 2019-08-01 大陸商南京傳奇生物科技有限公司 多重特異性抗原結合蛋白及其使用方法
JP7366908B2 (ja) 2018-01-15 2023-10-23 ナンジン レジェンド バイオテック カンパニー,リミテッド Pd-1に対する単一ドメイン抗体及びその変異体
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
KR102832460B1 (ko) 2018-02-20 2025-07-11 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MA53293A (fr) 2018-08-08 2021-11-17 Dragonfly Therapeutics Inc Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
MX2021001527A (es) 2018-08-08 2021-06-15 Dragonfly Therapeutics Inc Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
KR20210131373A (ko) * 2019-02-18 2021-11-02 커리어 테라퓨틱스, 인코포레이티드. 오르토폭스바이러스 주요 조직적합성 복합체(mhc) 클래스 i-유사 단백질(omcp) 및 종양-특이 결합 파트너를 사용한 이중특이적 융합 단백질
JP2022527761A (ja) * 2019-03-26 2022-06-06 フォーティ セブン, インコーポレイテッド がん治療のための多重特異性作用物質
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
EP4093745A4 (en) * 2020-01-20 2024-03-06 Wuxi Biologics Ireland Limited NEW WASH BUFFER SOLUTION FOR AFFINITY CHROMATOGRAPHY
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
JP2023545135A (ja) * 2020-10-12 2023-10-26 グレフェックス, インコーポレイテッド SARS-CoVタンパク質発現細胞に対するT細胞応答を標的にする抗体コンストラクト、それらの設計および使用
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
US20250345423A1 (en) * 2021-11-26 2025-11-13 Imunexus Therapeutics Limited Binding domain molecules on cell surfaces
CN115078718B (zh) * 2022-07-22 2024-11-12 福建师范大学 一种基于表面增强拉曼技术检测透明质酸酶的方法
EP4615859A2 (en) * 2022-11-09 2025-09-17 Repligen Corporation Affinity agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008096158A2 (en) * 2007-02-08 2008-08-14 Domantis Limited Antibody single variable domains against serum albumin
WO2010136492A2 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP221098A0 (en) * 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
EP1163339A1 (en) * 1999-04-01 2001-12-19 Innogenetics N.V. A polypeptide structure for use as a scaffold
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
DE112008003232T5 (de) * 2007-11-30 2011-02-24 Glaxo Group Limited, Greenford Antigen-Bindungskonstrukte
HRP20180045T1 (hr) * 2008-10-02 2018-03-23 Aptevo Research And Development Llc Proteini antagonisti cd86 koji se vežu na više meta
CA2763493A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Ltd. Antigen-binding proteins
WO2017143406A1 (en) * 2016-02-26 2017-08-31 Imunexus Pty Ltd Multi-specific molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008096158A2 (en) * 2007-02-08 2008-08-14 Domantis Limited Antibody single variable domains against serum albumin
WO2010136492A2 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins

Also Published As

Publication number Publication date
JP2022105574A (ja) 2022-07-14
CN109310766A (zh) 2019-02-05
US20240182542A1 (en) 2024-06-06
TW201734037A (zh) 2017-10-01
US20210230249A1 (en) 2021-07-29
US20210040177A1 (en) 2021-02-11
US20190338013A1 (en) 2019-11-07
EP3419667A1 (en) 2019-01-02
JP7536424B2 (ja) 2024-08-20
EP3419667A4 (en) 2019-10-23
AU2017222700A1 (en) 2018-03-22
WO2017143406A1 (en) 2017-08-31
AU2019200005A1 (en) 2019-01-24
JP2019510812A (ja) 2019-04-18
JP2024026531A (ja) 2024-02-28
US11345736B2 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
AU2017222700B2 (en) Multi-specific molecules
JP7076152B2 (ja) IgG結合ペプチドによる抗体の特異的修飾
JP6860601B2 (ja) 改変した抗体組成物、それを作製および使用する方法
US12324837B2 (en) ROR1-specific antigen binding molecules
KR102845959B1 (ko) Psma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
US11845793B2 (en) Anti-ROR1 antibodies
JP7482488B2 (ja) Cd137とpd-l1に特異的な新規融合タンパク質
RS61586B1 (sr) Anti-tfr antitela i njihova upotreba u lečenju proliferativnih i zapaljenjskih poremećaja
CN116761815A (zh) T细胞和嵌合刺激受体及其应用
JP2012511032A (ja) SPARC結合ScFv
JP7295098B2 (ja) 新規抗cd19抗体
KR20170110601A (ko) 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
US20230348627A1 (en) Anti-4-1bb-anti-pd-l1 bispecific antibody, and pharmaceutical composition and use thereof
JP2021502826A5 (enExample)
JP2023540526A (ja) ネクチン-4抗体およびそれの使用
EP2646472A1 (en) Covalently dimerized bivalent binding agents
KR20220161362A (ko) 다중특이적 항체를 작제하기 위한 플랫폼
CN113461820B (zh) 抗cd3人源化抗体
CN113461821B (zh) 抗cd3人源化抗体
Marshall et al. Engineering and characterization of a novel fusion protein incorporating B7. 2 and an anti–ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells
WO2023029089A1 (zh) 抗cd3人源化抗体
CN119137147A (zh) 具有增加的选择性的多链多靶向性双特异性抗原结合分子
KR20230098335A (ko) 클리핑 비율이 감소된 항원 결합 도메인
CN112543772A (zh) 双特异性抗体
KR20250085636A (ko) 신규 항-myct1 인간항체 및 이의 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: IMUNEXUS THERAPEUTICS LIMITED

Free format text: FORMER OWNER(S): IMUNEXUS PTY LTD